Alzamend Neuro Inc (ALZN)

$2.38 +0.01 (0.21%)
Market Cap 6.88M
Revenue (ttm) 0.00
Net Income (ttm) -4.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 62,300
Avg Vol 290,208
Day's Range N/A - N/A
Shares Out 2.90M
Stochastic %K 60%
Beta -0.32
Analysts Sell
Price Target $180.02

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 722 6333
Address:
3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
whateverhappenedthere
whateverhappenedthere Aug. 17 at 10:37 PM
$ALZN only down 99.99% so far, I’m in!
0 · Reply
XtremeBullz
XtremeBullz Aug. 13 at 8:47 PM
$ALZN $JAGX $TNFA $RNAZ /
0 · Reply
Marcos211
Marcos211 Aug. 13 at 7:59 PM
Watchers and Volume are picking up rapidly on ticker MTEX ! This could be the next multi - day runner! MTEX moves like a true nano nano floater! Show me some 100K buying candles and this could HALT UP and spike to 15+$ Some will buy now some will chase later! $JAGX $HCTI $ALZN $BBAI dips
0 · Reply
Dani_G_German
Dani_G_German Aug. 13 at 4:12 PM
$ALZN $GPUS I don’t trust this shiesty dude.
1 · Reply
SimSimBola
SimSimBola Aug. 12 at 7:27 PM
$ALZN one phone call to DoD
0 · Reply
SimSimBola
SimSimBola Aug. 12 at 6:16 PM
$ALZN we waiting DoD
0 · Reply
Dani_G_German
Dani_G_German Aug. 12 at 1:49 PM
$ALZN
0 · Reply
JoseGilberto109
JoseGilberto109 Aug. 8 at 11:09 PM
Wow what is happening to SNSE right now!? Seems like ALL volume and momentum are shifting into SNSE!! Could it be the next crazy runner of the day?? Only 500k float on SNSE - Bulls should keep it on watch!! Also watching: $JAGX $HCTI $ALZN $BBAIO swings
0 · Reply
HyperBulls
HyperBulls Aug. 8 at 7:49 PM
$ALZN Lithium
0 · Reply
Dani_G_German
Dani_G_German Aug. 8 at 2:29 PM
$ALZN market cap of 6mil this can explode on any news. Significant news towards the end of 25. This might be the time to buy and load
0 · Reply
Latest News on ALZN
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Jul 28, 2025, 8:00 AM EDT - 21 days ago

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Jul 23, 2025, 8:00 AM EDT - 26 days ago

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Jun 16, 2025, 8:00 AM EDT - 2 months ago

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 29, 2025, 8:00 AM EDT - 2 months ago

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 19, 2025, 8:00 AM EDT - 3 months ago

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 13, 2025, 8:00 AM EDT - 3 months ago

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Reverse Stock Split

May 8, 2025, 8:00 AM EDT - 3 months ago

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

May 7, 2025, 8:00 AM EDT - 3 months ago

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Mar 25, 2025, 8:00 AM EDT - 5 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Mar 18, 2025, 8:00 AM EDT - 5 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Mar 11, 2025, 8:00 AM EDT - 5 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Mar 4, 2025, 8:10 AM EST - 5 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Feb 25, 2025, 8:00 AM EST - 6 months ago

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Aug 19, 2024, 9:41 AM EDT - 1 year ago

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ABBV

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

May 7, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Apr 4, 2023, 6:30 AM EDT - 2 years ago

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

Nov 28, 2022, 6:30 AM EST - 2 years ago

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

Nov 22, 2022, 8:05 AM EST - 2 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

Nov 21, 2022, 7:27 PM EST - 2 years ago

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Nov 1, 2022, 6:30 AM EDT - 3 years ago

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 22, 2022, 8:00 AM EDT - 3 years ago

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 17, 2021, 11:59 PM EST - 3 years ago

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Dec 17, 2021, 9:54 AM EST - 3 years ago

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

See Why Alzamend Neuro Stock Is Rallying On Thursday

Sep 30, 2021, 1:45 PM EDT - 4 years ago

See Why Alzamend Neuro Stock Is Rallying On Thursday

Why Alzamend Neuro Shares Are Surging Higher Today

Sep 30, 2021, 11:54 AM EDT - 4 years ago

Why Alzamend Neuro Shares Are Surging Higher Today

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Sep 30, 2021, 10:11 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Sep 13, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Aug 4, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Jul 30, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 28, 2021, 3:07 PM EDT - 4 years ago

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Jul 23, 2021, 7:20 AM EDT - 4 years ago

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Jul 23, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 12, 2021, 6:00 AM EDT - 4 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Jul 1, 2021, 11:23 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 1, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 17, 2021, 4:30 PM EDT - 4 years ago

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Jun 16, 2021, 6:30 AM EDT - 4 years ago

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Alzamend Neuro Announces Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 4 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering

whateverhappenedthere
whateverhappenedthere Aug. 17 at 10:37 PM
$ALZN only down 99.99% so far, I’m in!
0 · Reply
XtremeBullz
XtremeBullz Aug. 13 at 8:47 PM
$ALZN $JAGX $TNFA $RNAZ /
0 · Reply
Marcos211
Marcos211 Aug. 13 at 7:59 PM
Watchers and Volume are picking up rapidly on ticker MTEX ! This could be the next multi - day runner! MTEX moves like a true nano nano floater! Show me some 100K buying candles and this could HALT UP and spike to 15+$ Some will buy now some will chase later! $JAGX $HCTI $ALZN $BBAI dips
0 · Reply
Dani_G_German
Dani_G_German Aug. 13 at 4:12 PM
$ALZN $GPUS I don’t trust this shiesty dude.
1 · Reply
SimSimBola
SimSimBola Aug. 12 at 7:27 PM
$ALZN one phone call to DoD
0 · Reply
SimSimBola
SimSimBola Aug. 12 at 6:16 PM
$ALZN we waiting DoD
0 · Reply
Dani_G_German
Dani_G_German Aug. 12 at 1:49 PM
$ALZN
0 · Reply
JoseGilberto109
JoseGilberto109 Aug. 8 at 11:09 PM
Wow what is happening to SNSE right now!? Seems like ALL volume and momentum are shifting into SNSE!! Could it be the next crazy runner of the day?? Only 500k float on SNSE - Bulls should keep it on watch!! Also watching: $JAGX $HCTI $ALZN $BBAIO swings
0 · Reply
HyperBulls
HyperBulls Aug. 8 at 7:49 PM
$ALZN Lithium
0 · Reply
Dani_G_German
Dani_G_German Aug. 8 at 2:29 PM
$ALZN market cap of 6mil this can explode on any news. Significant news towards the end of 25. This might be the time to buy and load
0 · Reply
Runmaster83
Runmaster83 Aug. 8 at 1:02 PM
$ALZN This could run on lithium news…..🗞️ Sleeping giant.
0 · Reply
TimA2020
TimA2020 Aug. 7 at 10:33 PM
$ALZN Alzamend Neuro (NASDAQ: ALZN) has initiated dosing in its Phase II clinical trial of AL001, a novel lithium formulation, at Massachusetts General Hospital. The study aims to compare AL001's brain absorption and blood levels against existing lithium carbonate products in healthy subjects. Topline data is expected by the end of 2025. AL001 represents a potential breakthrough in lithium-based treatments, as previous mouse studies demonstrated improved brain absorption with lower blood levels, potentially eliminating the need for therapeutic drug monitoring (TDM). This advancement could benefit over 43 million Americans affected by Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD.
0 · Reply
SimSimBola
SimSimBola Aug. 7 at 7:04 PM
$ALZN PR! PR! PR! PR!
0 · Reply
SimSimBola
SimSimBola Aug. 7 at 7:01 PM
$ALZN 😎
0 · Reply
TimA2020
TimA2020 Aug. 7 at 3:26 PM
$ALZN https://www.cnn.com/2025/08/06/health/lithium-alzheimers-brain-study
0 · Reply
1KEI
1KEI Aug. 6 at 11:11 PM
$ALZN https://hms.harvard.edu/news/could-lithium-explain-treat-alzheimers-disease
0 · Reply
HetroBabadook
HetroBabadook Aug. 6 at 8:27 PM
$JAGX $HCTI $ALZN $BBAI If you are looking for a place to lose all your money through reverse splits and have no future, then invest in this persons grift
0 · Reply
Marcos211
Marcos211 Aug. 6 at 8:21 PM
Looks like volume and momentum are going to be shifting back in to CMCT now! Shorts overextended and now bulls can have them trapped at the bottom. CMCT Could make a huge multi day run - only 500k float for public! Don't miss CMCT ... it's breaking out now! $JAGX $HCTI $ALZN $BBAI ns
1 · Reply
SimSimBola
SimSimBola Aug. 6 at 6:32 PM
$ALZN there is a security guard standing at 2.30 about 9000 feet tall. who is going to move him?
1 · Reply
YoloAlfred
YoloAlfred Aug. 6 at 5:56 PM
$ALZN 🧐🧐🧐🤔🤔🤔🤔🤔🤔🤔🤔🤔
0 · Reply
ItTakesItAll
ItTakesItAll Aug. 6 at 10:13 AM
$STKH lets go again, got only 75% last call and missing 25%, make up time $ONCO $BSLK $ALZN $OPAD read to go again, oversold and undervalued, imho.
5 · Reply
swagmastersupreme
swagmastersupreme Aug. 6 at 9:58 AM
$ALZN should have breaking news today.
1 · Reply